VIVIAN UMEUGO: Open Payments
NPI 1609371046 · UPPER MARLBORO, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,109 in 65 payments from 13 companies in 2025. Trend: 2023 $1,356 · 2024 $2,019 · 2025 $2,109
Food & beverage: $2,106Education: $4
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 7 | $392 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $392 |
| Otsuka America Pharmaceutical, Inc. | 10 | $281 |
| Supernus Pharmaceuticals, Inc. | 8 | $229 |
| Teva Pharmaceuticals USA, Inc. | 6 | $210 |
| Alkermes, Inc. | 8 | $203 |
| Janssen Pharmaceuticals, Inc | 3 | $114 |
| Vanda Pharmaceuticals Inc. | 3 | $89 |
| Janssen Scientific Affairs, LLC | 1 | $58 |
| ABBVIE INC. | 2 | $42 |
Products named: COBENFY, CAPLYTA, Qelbree, REXULTI, UZEDY, INVEGA SUSTENNA, ARISTADA, ABILIFY ASIMTUFII.
Industry payments across MD — which companies pay providers there.
